Zedsen partners with Imperial College Healthcare NHS Trust to clinically validate its novel non-invasive sensing technology

The clinical research study is titled "An Investigation into Dielectric Assessment of Permittivity of Cancer in Human Using a Novel Electrical Capacitance Tomography Scanner," or "DiCECT" and comprises 90 participants at Charing Cross Hospital. The study is split into 2 parts, with Part A recruiting 20 participants to assess whether the Z-Scanner results can be repeated and reproduced by different users and devices. Part B will recruit 70 participants to assess whether the Z-Scanner can differentiate between benign and cancerous lesion.
Comunicato Precedente

next
Comunicato Successivo

next
Preferisci Informazione.News su Google

The clinical research study is titled "An Investigation into Dielectric Assessment of Permittivity of Cancer in Human Using a Novel Electrical Capacitance Tomography Scanner," or "DiCECT" and comprises 90 participants at Charing Cross Hospital. The study is split into 2 parts, with Part A recruiting 20 participants to assess whether the Z-Scanner results can be repeated and reproduced by different users and devices. Part B will recruit 70 participants to assess whether the Z-Scanner can differentiate between benign and cancerous lesion.

"This is a hugely exciting time for Zedsen, commencing the clinical research study is a major milestone for the company and for the team. We will be eagerly anticipating the outcome of the study and being one step closer to bringing our revolutionary technology to market." Michael Lynch, CEO

Zedsen have engaged with leading experts in the field of oncology and radiology to help incept the research study, one of whom is acting as Principal Investigator for the study.

"I am very excited about the prospect of this technology. Should it perform as well as we hope it will, it could be a gamechanger in oncological diagnostics." Professor Adrian Lim, Consultant Radiologist

Zedsen partners with Imperial College Healthcare NHS Trust to clinically validate its novel non-invasive sensing technology

The study commences in January 2024 and is due to run until December 2024 at Charing Cross Hospital.

www.zedsen.com

Media Contact - Amelia Beaumont, amelia@zedsen.com, 07940 524109

Logo: https://mma.prnewswire.com/media/2153040/4476524/Zedsen_Logo.jpg

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/zedsen-partners-with-imperial-college-healthcare-nhs-trust-to-clinically-validate-its-novel-non-invasive-sensing-technology-302027800.html

Ufficio Stampa

 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom

Allegati
Slide ShowSlide Show
Non disponibili
;